Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Citi
Deloitte
UBS
Harvard Business School
Baxter
Boehringer Ingelheim
McKesson
QuintilesIMS

Generated: July 21, 2018

DrugPatentWatch Database Preview

ABBVIE Company Profile

« Back to Dashboard

Summary for ABBVIE
International Patents:1284
US Patents:81
Tradenames:77
Ingredients:64
NDAs:89
Drug Master File Entries: 1
Patent Litigation for ABBVIE: See patent lawsuits for ABBVIE

Drugs and US Patents for ABBVIE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie PLACIDYL ethchlorvynol CAPSULE;ORAL 010021-010 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 AB RX Yes Yes 7,041,319 ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No 6,713,086*PED ➤ Sign Up Y ➤ Sign Up
Abbvie K-TAB potassium chloride TABLET, EXTENDED RELEASE;ORAL 018279-001 Approved Prior to Jan 1, 1982 AB3 RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ABBVIE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-002 May 30, 1997 5,643,607 ➤ Sign Up
Abbvie Endocrine Inc LUPRON DEPOT-PED leuprolide acetate INJECTABLE;INJECTION 020263-006 Jan 21, 1994 4,005,063 ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 5,212,326*PED ➤ Sign Up
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020011-001 Oct 22, 1990 4,677,191 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 2009-08-04
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 2004-05-03
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 2009-09-02
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 2010-05-10
➤ Subscribe Tablets 2.5 mg/200 mg ➤ Subscribe 2006-02-24
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Tablets 100 mg/25 mg ➤ Subscribe 2008-12-23
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 2008-10-14
➤ Subscribe Oral Solution 80 mg/20 mg per mL ➤ Subscribe 2014-06-19
➤ Subscribe Gel Metered-dose Pump 1% ➤ Subscribe 2008-12-19
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 2007-11-09
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 2007-07-24
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2009-08-12
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2005-02-08
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 2009-09-01
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19
➤ Subscribe Extended-release Tablet 500 mg ➤ Subscribe 2010-12-06
➤ Subscribe Tablets 5 mg/200 mg ➤ Subscribe 2005-05-27
➤ Subscribe Gel 1.62% ➤ Subscribe 2012-04-06
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 2008-11-28
➤ Subscribe Gel 1.62% (1.25 g and 2.5 g packets) ➤ Subscribe 2013-06-19
➤ Subscribe Capsules 4 mcg ➤ Subscribe 2008-08-25
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 2004-10-04
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2008-02-20

Non-Orange Book US Patents for ABBVIE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,193,367 Polymorph of a pharmaceutical ➤ Sign Up
6,592,903 Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate ➤ Sign Up
7,695,739 In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions ➤ Sign Up
8,652,464 Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for ABBVIE Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00013 Denmark ➤ Sign Up PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150115
C/GB08/036 United Kingdom ➤ Sign Up PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
0900 Netherlands ➤ Sign Up PRODUCT NAME: GLECAPREVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/17/1213 20170728
0731 Netherlands ➤ Sign Up PRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Healthtrust
Mallinckrodt
Colorcon
Express Scripts
Argus Health
US Army
Merck
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.